alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Sheet: Sheet1

Sheet: Sheet2

SYSTEM DESIGNATION

DATE PLANNING REPORT COMPLETED

                SUMMARY OF SYSTEM

                  PLANNING REPORT

PLANNING ENGINEER

35254.0

           PART  I    GENERAL  DATA

             2.  LINE MILES

   3.  NO. OF CONSUMERS

   7.  PAST PEAK LOAD

DESIGN

TOTAL

TOTAL

TOTAL

LOAD

ALL TYPES

SPECIAL

SYSTEM

SPECIAL

YEARLY SALES

kWh/CONS.

kWh/CONS.

ITEMS

TRANS.

DISTR.

(Including

LOADS

kWh

/MO.

DATE

/MO.

special loads)

PEAK MO.

    1.

a.

b.

c.

d.

4.

5.

6.

a.

b.

8.

PRESENT

SYSTEM AS

OF________

LONG RANGE

     PLAN

  PART  II    LINE  MILES

               2.  DISTRIBUTION

            3.  TRANSMISSION

     ITEMS

12.5/7.2 kV

24.9/14.4 kV

________ kV

_________ kV

________ kV

_________ kV

________ kV

_________ kV

         1.

a.

b.

  c.

  d.

    a.

    b.

  c.

  d.

PRESENT SYSTEM

AS OF ___________

LONG RANGE 

PLAN

                           PART  III    SUBSTATIONS  AND  METERING  POINTS

                           3.   PRESENT  SYSTEM

   4.   LONG  RANGE  PLAN

NAME OR LOCATION*

      POWER SUPPLIER

kV

kV

kV

kV

MVA

PRIMARY

SECONDARY

MVA

PRIMARY

SECONDARY

1.

2.

a.

b.

c.

a.

b.

c.

ITEMS      

TRANSMISSION

ALL

DISTR. TRANSFORMERS

ALL OTHER DISTR.

TOTAL T & D

GENERAL &

LINES

SUBSTATIONS

METERS & SERVICES

FACILITIES

PLANT

PROD. PLANT

1.       

2.

3.

4.

5.

6.

7.

PRESENT SYSTEM AS

0.0

OF ____________

LONG RANGE PLAN

0.0

  RUS  FORM    261            REV.   1-95  (CAB 7/96)

 *  Include those furnished by Power Supplier and designate with asterisk.

 REMARKS:

INSTRUCTIONS

Part  I -

List  data  as  indicated  by  column  headings.

determined  from  his  "Analysis  of  Present  System  and  Basic  Data."

Part II -

List the mileage breakdown of all distribution and transmission lines in the present system and similar data for

the  long  range  plan.

Part III -

List  data  for  each  substation  or  metering  point  as  indicated  in  the  column  headings.

Part IV -

following accounts:

Column  2  -  350 + 351 + 352 + 354 + 355 + 356 + 357 + 358 + 359 

Column  3  -  353 + 362

Column  4  -  368 + 369 + 370

Column  5  -  360 + 361 + 364 + 365 + 366 + 367 + 371 + 372 + 373

Column  7  -  Sum of 389 thru 398 + Sum of 310 thru 345 as applicable.

  RUS  FORM    261            REV.   1-95 (CAB 7/96)
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1329 Glyceryl palmitostearate. ( a ) Glyceryl palmitostearate is a mixture of mono-, di-, and triglyceryl esters of palmitic and stearic acids made from glycerin, palmitic acid, and stearic acid.
( b ) The ingredient meets the following specifications: ( 1 ) The substance is a mixture of mono-, di-, and triglycerides of palmitic acid and stearic acid.
( 2 ) Heavy metals (as lead): Not more than 10 parts per million.
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as a formulation aid, as defined in § 170.3(o)(14) of this chapter.
( 2 ) The ingredient is used in excipient formulations for use in tablets at levels not to exceed good manufacturing practice.
[60 FR 63621, Dec. 12, 1995]
§ 163.135 Buttermilk chocolate. ( a ) *Description.* Buttermilk chocolate is the food that conforms to the standard of identity, and is subject to the requirements for label declaration of ingredients for milk chocolate in § 163.130, except that: ( 1 ) The optional dairy ingredients are limited to sweet cream buttermilk, concentrated sweet cream buttermilk, dried sweet cream buttermilk, and any combination of these; and
( 2 ) The finished buttermilk chocolate contains less than 3.39 percent by weight of milkfat and not less than 12 percent by weight of sweet cream buttermilk solids based on those dairy ingredients specified in paragraph (a)(1) of this section, exclusive of any added sweetener or other dairy-derived ingredient that is added beyond that amount that is normally present in the specified dairy ingredient.
( b ) *Nomenclature.* The name of the food is “buttermilk chocolate”, “buttermilk chocolate coating”, “sweet buttermilk chocolate”, “sweet buttermilk chocolate coating”, “sweet cream buttermilk chocolate”, or “sweet cream buttermilk chocolate coating”.
#### Commonwealth v. Benjamin

*Edward M. David,*for petitioner.

*G. Wesley Allen,*for respondent.

December 18, 1950.

Bonniwell, J.,

— Thomas Benjamin and Eugenia Benjamin were married on June 23,1937, in the Virgin Islands. When the couple came to Philadelphia from the Virgin Islands they brought with them, as members of their family, two minor children, Mary Abramson, bom December 14, 1941, and Ovin Labert, bom September 4,1945. Neither were the children of the Benjamins, nor related to them, or ever legally adopted. They voluntarily befriended and assumed the care of Mary Abramson when she was five months old, and of Ovin Labert since he was three weeks of age. The Benjamins separated on September 15,1950. On November 21,1950, we made a temporary order on Thomas Benjamin of $10 per week for the support of his wife, and reserved our decision as to an order for the children. The question we must determine is whether Thomas Benjamin is legally liable for the continued support of Mary Abramson and Ovin Labert.

When defendant took upon himself the care and maintenance of the children and brought them from the Virgin Islands as members of his family he put himself in loco parentis.

In 46 C. J. 1334, §174, quoted and relied upon in Commonwealth v. Behmer, 20 D. & C. 664 (Centre County, 1934), we find that:

> *48“A person standing in loco parentis to a child is one who has put himself in the situation of a lawful parent by assuming the obligations incident to the parental relation, without going through the formalities necessary to a legal adoption, and the rights, duties, and liabilities of such person are the same as those of the lawful parent. The assumption of the relation is a question of intention, which may be shown by the acts and declarations of the person alleged to stand in that relation.”

In Young v. Hipple, 273 Pa. 439, Mr. Justice Simpson held (p. 447) :

> “Upon a consideration of the decisions in other branches of the law, it appears that where one stands in loco parentis to another, the rights and liabilities arising out of that relation, are, as the words imply, exactly the same as between parent and child.”

The law clearly says that where, as here, defendant received the children into his home when they were infants, raised and treated them as his own, that relation arose, and the law presumes the continuance of a status shown to exist: Young v. Hipple, supra, 448.

The obligation to support a child is imposed upon a parent by law. The law makes that a legal duty, which the law of society makes a moral duty. The public has an interest in its performance, as the proper maintenance of all members of the community is a matter of public concern. Since the law imposes a legal duty to perform his obligation to provide for his children, he must provide for these children, to whom he stands in loco parentis.

Accordingly, we make permanent the temporary order of $10 per week for the support of defendant’s wife, Eugenia Benjamin, and to pay the further additional sum of $10 per week for the support of the two minor children, Mary Abramson and Ovin Labert.
#### People of the State of Illinois, Plaintiff-Appellee, v. Marvin Earl Miller, Defendant-Appellant.

Gen. No. 11,072. (Abstract of Decision.)

Fourth District.

July 15,1969.

Norbert J. Goetten, of Jerseyville, for appellant; Alvin H. Petitt, State’s Attorney of Jersey County, of Jerseyville, for appellee.

Opinion by PRESIDING JUSTICE TRAPP. Not to be published in full.
Editorial Note on Part 312
Editorial Note: Nomenclature changes to part 312 appear at 69 FR 13717, Mar. 24, 2004.

§ 312.1 Scope. ( a ) This part contains procedures and requirements governing the use of investigational new drugs, including procedures and requirements for the submission to, and review by, the Food and Drug Administration of investigational new drug applications (IND's). An investigational new drug for which an IND is in effect in accordance with this part is exempt from the premarketing approval requirements that are otherwise applicable and may be shipped lawfully for the purpose of conducting clinical investigations of that drug.
( b ) References in this part to regulations in the Code of Federal Regulations are to chapter I of title 21, unless otherwise noted.
Table of Contents

Chapter2

Mission Essential Task List

```
Task: Deploy to Theater of Operations                       2-2         8

Task: Conduct an Operational Move                           2-3        11

Task: Support a Movement to Contact                         2-4        15

Task: Support an Attack                                     2-5        22

Task: Support a Defense                                     2-6        30

Task: Prepare for a Subsequent Mission                      2-7        37
```

----
### IN THE SUPREME COURT OF THE STATE OF MONTANA DA 23 - 06 77

_________________ JUAN ANASTASIO RODRIGUEZ ,

Petitioner and Appellant, v. STATE OF MONTANA,

Respondent and Appellee. A M E N D E D O R D E R

_________________ Pursuant to Appellant’s motion for a 12 0 - day extension to time to file the opening brief and good cause appearing, IT IS HEREBY ORDERED that Appellant is given an extension of time to and including August 20 , 2024, to file the opening brief.

Electronically signed by: Mike McGrath Chief Justice, Montana Supreme Court

April 29 2024

04/29/2024
Case Number: DA 23-0677
[No. 16471-3-III.

Division Three.

November 13, 1997.]

#### *In the Matter of the Personal Restraint of*Ronald Lee Judd, *Petitioner.*

Petition for relief from personal restraint. *Granted*by unpublished opinion per Kato, J., concurred in by Kurtz and Brown, JJ.
#### § 20.50 Nonspecific and overly burdensome requests.

The Food and Drug Administration will make every reasonable effort to comply fully with all requests for disclosure of nonexempt records. Nonspecific requests or requests for a large number of documents that require the deployment of a substantial amount of agency man-hours to search for and compile will be processed taking into account the staff-hours required, the tasks from which these resources must be diverted, the impact that this diversion will have upon the agency's consumer protection activities, and the public policy reasons justifying the requests. A decision on the processing of such a request for information shall be made after balancing the public benefit to be gained by the disclosure against the public loss that will result from diverting agency personnel from their other responsibilities. In any situation in which it is determined that a request for voluminous records would unduly burden and interfere with the operations of the Food and Drug Administration, the person making the request will be asked to be more specific and to narrow the request, and to agree on an orderly procedure for the production of the requested records, in order to satisfy the request without disproportionate adverse effects on agency operations.

[42 FR 15616, Mar. 22, 1977. Redesignated at 68 FR 25286, May 12, 2003]
§ 333.203 Definitions. As used in this subpart: ( a ) *Antifungal.* A drug which inhibits the growth and reproduction of fungal cells and decreases the number of fungi present.
( b ) *Athlete's foot.* An infection of the feet caused by certain dermatophytic fungi.
( c ) *Dermatophyte.* A fungus that invades and lives upon the skin or in the hair or nails.
( d ) *Fungus.* Any of a large division of plants, including dermatophytes, yeasts, and molds, characterized by a simple cell structure and the absence of chlorophyll.
( e ) *Jock itch.* A chronic and recurrent infection caused by certain dermatophytic fungi; affects the upper, inner thighs and sometimes extends to the groin and the pubic area; the condition most frequently occurs in men, but may also occur in women.
( f ) *Ringworm.* A skin infection caused by certain dermatophytic fungi.
EXHIBIT 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the Registration Statements (Form S-8 No. 33-99740, Form S-8 No. 33-40365 and Form S-8 No. 333-9162) pertaining to the Power Control Technologies Inc. 1995 Stock Option Plan, the M & F Worldwide 1997 Stock Option Plan, and the M & F Worldwide Corp. 2000 Stock Option Plan of M & F Worldwide Corp. of our reports dated March 6, 2007, with respect to the consolidated financial statements and schedules of M & F Worldwide Corp., M & F Worldwide Corp. management’s assessment of the effectiveness of internal control over financial reporting and the effectiveness of internal control over financial reporting of M & F Worldwide Corp., included in this Annual Report (Form 10-K) for the year ended December 31, 2006.

|  | /s/ Ernst & Young LLP |
|--|---------------------------|

New York, New York March 6, 2007

----
Fourth Court of Appeals

San Antonio, Texas

JUDGMENT

No. 04-14-00206-CV

PMSALS 1, LLC,

Appellant

v.

ROSENTHAL PAUERSTEIN SANDOLOSKI AGATHER L.L.P. and Jonathan Starr,

Appellees

From the 438th Judicial District Court, Bexar County, Texas

Trial Court No. 2013-CI-17620

Honorable Olin B. Strauss, Judge Presiding

BEFORE CHIEF JUSTICE STONE, JUSTICE ANGELINI, AND JUSTICE MARION

In accordance with this court’s opinion of this date, the joint motion to dismiss this appeal 

is GRANTED, and the appeal is DISMISSED. Costs of the appeal are taxed against the parties 

who incurred them.

SIGNED October 8, 2014.

_________________________________

Catherine Stone, Chief Justice
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>                     <C>
<PERIOD-TYPE>                   3-MOS                   6-MOS
<FISCAL-YEAR-END>                          JUN-30-1998             JUN-30-1998
<PERIOD-START>                             OCT-01-1997             JUL-01-1997
<PERIOD-END>                               DEC-31-1997             DEC-31-1997
<CASH>                                           9,294                   9,294
<SECURITIES>                                 4,004,525               4,004,525
<RECEIVABLES>                               11,634,583              11,634,583
<ALLOWANCES>                                   450,234                 450,234
<INVENTORY>                                 13,393,530              13,393,530
<CURRENT-ASSETS>                            30,544,512              30,544,512
<PP&E>                                       9,626,385               9,626,385
<DEPRECIATION>                               4,475,147               4,475,147
<TOTAL-ASSETS>                              35,951,259              35,951,259
<CURRENT-LIABILITIES>                       10,399,842              10,399,842
<BONDS>                                        496,582                 496,582
<PREFERRED-MANDATORY>                                0                       0
<PREFERRED>                                          0                       0
<COMMON>                                    20,131,196              20,131,196
<OTHER-SE>                                   4,923,639               4,923,639
<TOTAL-LIABILITY-AND-EQUITY>                35,951,259              35,951,259
<SALES>                                     16,259,428              32,289,219
<TOTAL-REVENUES>                            16,259,428              32,289,219
<CGS>                                       13,488,909              26,787,145
<TOTAL-COSTS>                               13,488,909              26,787,145
<OTHER-EXPENSES>                             1,336,204               2,693,749
<LOSS-PROVISION>                                     0                       0
<INTEREST-EXPENSE>                                   0                       0
<INCOME-PRETAX>                              1,434,315               2,808,325
<INCOME-TAX>                                   487,667                 954,831
<INCOME-CONTINUING>                            946,648               1,853,494
<DISCONTINUED>                                       0                       0
<EXTRAORDINARY>                                      0                       0
<CHANGES>                                            0                       0
<NET-INCOME>                                   946,648               1,853,494
<EPS-PRIMARY>                                      .18                     .35
<EPS-DILUTED>                                      .17                     .33
        


</TABLE>
§ 320.23 Basis for measuring in vivo bioavailability or demonstrating bioequivalence. ( a ) ( 1 ) The in vivo bioavailability of a drug product is measured if the product's rate and extent of absorption, as determined by comparison of measured parameters, e.g., concentration of the active drug ingredient in the blood, urinary excretion rates, or pharmacological effects, do not indicate a significant difference from the reference material's rate and extent of absorption. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by scientifically valid measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of action.
( 2 ) Statistical techniques used must be of sufficient sensitivity to detect differences in rate and extent of absorption that are not attributable to subject variability.
( 3 ) A drug product that differs from the reference material in its rate of absorption, but not in its extent of absorption, may be considered to be bioavailable if the difference in the rate of absorption is intentional, is appropriately reflected in the labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug product.
( b ) ( 1 ) Two drug products will be considered bioequivalent drug products if they are pharmaceutical equivalents or pharmaceutical alternatives whose rate and extent of absorption do not show a significant difference when administered at the same molar dose of the active moiety under similar experimental conditions, either single dose or multiple dose. Some pharmaceutical equivalents or pharmaceutical alternatives may be equivalent in the extent of their absorption but not in their rate of absorption and yet may be considered bioequivalent because such differences in the rate of absorption are intentional and are reflected in the labeling, are not essential to the attainment of effective body drug concentrations on chronic use, and are considered medically insignificant for the particular drug product studied.
( 2 ) For drug products that are not intended to be absorbed into the bloodstream, bioequivalence may be demonstrated by scientifically valid methods that are expected to detect a significant difference between the drug and the listed drug in safety and therapeutic effect.
[57 FR 17999, Apr. 28, 1992, as amended at 67 FR 77673, Dec. 19, 2002, 81 FR 69658, Oct. 6, 2016]
###### Editorial Note on [Part 184](/current/title-21/part-184?toc=1)

#### Editorial Note:

Nomenclature changes to part 184 appear at [66 FR 56035](https://www.federalregister.gov/citation/66-FR-56035), Nov. 6, 2001; [66 FR 66742](https://www.federalregister.gov/citation/66-FR-66742), Dec. 27, 2001; [68 FR 15355](https://www.federalregister.gov/citation/68-FR-15355), Mar. 31, 2003; [69 FR 13717](https://www.federalregister.gov/citation/69-FR-13717), Mar. 24, 2004; [70 FR 40880](https://www.federalregister.gov/citation/70-FR-40880), July 15, 2005; [70 FR 67651](https://www.federalregister.gov/citation/70-FR-67651), Nov. 8, 2005; and [81 FR 49897](https://www.federalregister.gov/citation/81-FR-49897), July 29, 2016.

#### § 184.1262 Corn silk and corn silk extract.

(a) Corn silk is the fresh styles and stigmas of *Zea mays* L. collected when the corn is in milk. The filaments are extracted with dilute ethanol to produce corn silk extract. The extract may be concentrated at a temperature not exceeding 60 °C.

(b) The ingredient must be of a purity suitable for its intended use.

(c) In accordance with [§ 184.1(b)(2)](/on/2024-09-17/title-21/section-184.1#p-184.1(b)(2)), the ingredients are used in food only within the following specific limitations:

| Category of food | Maximum level of use in food (as served)1 | Functional use |
| --- | --- | --- |
| Baked goods and baking mixes, [§ 170.3(n)(1) of this chapter](/on/2024-09-17/title-21/section-170.3#p-170.3(n)(1)) | 30 | Flavoring agent, [§ 170.3(o)(12) of this chapter](/on/2024-09-17/title-21/section-170.3#p-170.3(o)(12)). |
| Nonalcoholic beverages, [§ 170.3(n)(3) of this chapter](/on/2024-09-17/title-21/section-170.3#p-170.3(n)(3)) | 20 | Do. |
| Frozen dairy desserts, [§ 170.3(n)(20) of this chapter](/on/2024-09-17/title-21/section-170.3#p-170.3(n)(20)) | 10 | Do. |
| Soft candy, [§ 170.3(n)(38) of this chapter](/on/2024-09-17/title-21/section-170.3#p-170.3(n)(38)) | 20 | Do. |
| All other food categories | 4 | Do. |
| | | |
| --- | --- | --- |
| 1 Parts per million. | | |

(d) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.

[[47 FR 29953](https://www.federalregister.gov/citation/47-FR-29953), July 9, 1982, as amended at [73 FR 8607](https://www.federalregister.gov/citation/73-FR-8607), Feb. 14, 2008]
#### § 516.22 Permanent-resident U.S. agent for foreign sponsor.

Every foreign sponsor that seeks MUMS-drug designation shall name a permanent resident of the United States as the sponsor's agent upon whom service of all processes, notices, orders, decisions, requirements, and other communications may be made on behalf of the sponsor. Notifications of changes in such agents or changes of address of agents should preferably be provided in advance, but not later than 60 days after the effective date of such changes. The permanent-resident U.S. agent may be an individual, firm, or domestic corporation and may represent any number of sponsors. The name and address of the permanent-resident U.S. agent shall be provided to the Director of the Office of Minor Use and Minor Species Animal Drug Development.